- Tech Portfolio - Products
- Tissue 2 Target Service
April 24-30, 2020, San Diego Convention Center, San Diego, CA
Come see Cellecta at Booth 1904.
Register for our Technology Workshop today.
Monday, April 27, 2020 * 12:30-1:30 pm Spotlight Theatre C in the Exhibit Hall
CRISPR/Cas9 screens to investigate mechanisms of cancer drug resistance
Presenters Paul Diehl, PhD, COO, Cellecta and Guotai Xu, PhD, Memorial Sloan Kettering Cancer Center (MSKCC)
After a brief introduction of Cellecta technologies by Paul Diehl, Guotai Xu, from MSKCC will speak about recently published research on endocrine therapy resistance.
Over 70% of breast cancers depend on Estrogen-Receptor (ER) for growth and are treated with endocrine therapy. 40% of those tumors also harbor mutations in the PIK3CA gene, which are targeted by PI3Kα inhibitor alpelisib in the clinic. However, intrinsic and adaptive drug resistance is the norm with these agents, and mechanisms of resistance are still largely unknown in the clinic. Dr. Xu will discuss the results from CRISPR/Cas9 screens that may improve understanding of endocrine therapy and PI3Kα inhibitor resistance, and may assist in the development of therapeutic strategies to prevent or revert this resistance.
Please register for the April 27 event. Space is limited.
Register for the Cellecta AACR Technology Workshop here>
Wednesday, April 29, 2020 * 9:00 am - 12:30 pm
Visit our Poster at Board 18, Abstract # 5868
Cell barcoding, genetic screens and expression profiling at a single-cell levelView Event